Dr. Hans Lee currently serves as the Director of Multiple Myeloma Research at the Sarah Cannon Research Institute (SCRI). Prior to his move to SCRI, he was an Associate Professor and Director of Multiple Myeloma Clinical Research in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center. He received his MD from Indiana University. Subsequently, he completed his internal medicine residency training at Washington University in St. Louis, followed by a hematology/oncology fellowship at MD Anderson Cancer Center. Dr. Lee's clinical and research efforts are focused on advancing the care and treatment of patients with multiple myeloma and other plasma cell dyscrasias. In addition to his leadership role at SCRI, Dr. Lee serves as a medical oncologist at SCRI Oncology Partners in Nashville, Tennessee.

Mark Schroeder, MD, is Associate Professor of Medicine, Division of Oncology, Section of Blood and Marrow Transplantation at Washington University School of Medicine. Dr. Schroeder is a graduate of the University of Cincinnati College of Medicine and completed his residency in Internal Medicine and fellowship in Hematology and Oncology at Washington University in St. Louis. He joined faculty at Washington University in 2009. He is a member of the Siteman Cancer Center and serves on the National Comprehensive Cancer Network Hematopoietic Cell Transplant Panel. Dr. Schroeder’s clinical research focuses on multiple myeloma, graft versus host disease, and stem cell transplant biology.

Dr. Minoo Battiwalla, M.D., M.S. joined Sarah Cannon in 2018 as the director of outcomes research. In his role, he designs and leads retrospective outcomes research across the Sarah Cannon Blood Cancer Network with a special emphasis on blood and marrow stem cell transplantation and cellular therapy.

Gayathri Ravi, MD, is an Assistant Professor in the Division of Hematology & Oncology at the University of Alabama at Birmingham (UAB) School of Medicine. She is also an Associate Scientist at the UAB O’Neal Comprehensive Cancer Center. Her work focuses on clinical care and academic contributions within hematologic malignancies.

Muhamed Baljevic, MD is a hematologist and medical oncologist at Vanderbilt University Medical Center, where he joined the faculty in 2021. He serves as Director of Plasma Cell Disorders Research and leads the Vanderbilt Amyloidosis Multidisciplinary (VAMP) program. Dr. Baljevic’s clinical and research focus includes multiple myeloma, AL amyloidosis, and other plasma cell disorders, with particular interest in treatment resistance, post-transplant immune recovery, and novel approaches for relapsed and refractory disease.

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.